Atea Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVIR research report →
About the company
Atea Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
- CEO
- Jean-Pierre Sommadossi
- IPO
- 2020
- Employees
- 55
- HQ
- Boston, MA, US
Price Chart
- Market Cap
- $398.53M
- P/E
- -2.33
- P/S
- 0.00
- P/B
- 1.69
- EV/EBITDA
- -1.78
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -57.01%
- ROIC
- -78.11%
- Revenue
- $0 · 0.00%
- Net Income
- $-158,349,000 · 5.96%
- EPS
- $-1.94 · 3.00%
- Op Income
- $-180,887,000
- FCF YoY
- 2.56%
- 52W High
- $6.45
- 52W Low
- $2.78
- 50D MA
- $4.75
- 200D MA
- $4.17
- Beta
- 0.32
- Avg Volume
- 330.30K
Get TickerSpark's AI analysis on AVIR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 18, 26 | Lucidi Bruno | other | 29,600 |
| Jun 18, 26 | Lucidi Bruno | other | 37,700 |
| Jun 18, 26 | Lucidi Bruno | other | 26,700 |
| Jun 18, 26 | Lucidi Bruno | other | 29,600 |
| Jun 18, 26 | BERGER FRANKLIN M | other | 29,600 |
| Jun 18, 26 | BERGER FRANKLIN M | other | 37,700 |
| Jun 18, 26 | BERGER FRANKLIN M | other | 26,700 |
| Jun 18, 26 | BERGER FRANKLIN M | other | 29,600 |
| Jun 18, 26 | Berman Howard | other | 37,700 |
| Jun 18, 26 | Berman Howard | other | 26,700 |
Our AVIR coverage
Recent articles, reports, and earnings notes.
Want a deeper read on AVIR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.